The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The GLP-1 Analogues Market was valued at approximately USD 37 Billion in 2023 and is expected to grow at a substantial CAGR of around 28% during the forecast period (2024-2032) owing to the rising ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Objectives The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Drugs like semaglutide, liraglutide or tirzepatide (a dual GLP-1 and GIP analog) have led to significant weight reduction of participants in clinical trials and in real-world settings, making them ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention ...

It was hard enough in the analogue era, but social media influencers ... With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people ...